Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SubtleGAD vs Standard Dose Gadobutrol CNS Imaging
NCT06224543Phase 1Completed
- Sponsor
- Subtle Medical
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Subtle Medical. Primary endpoint: Enhancement of SubtleGAD in 10% dose and 25% dose gadobutrol MR images. Started Jun 2023; status: completed.
Beyond the preview
Go deeper on NCT06224543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224543.